TSB Therapeutics (Beijing) CO.LTD
Clinical-stage biopharmaceutical company focused on therapeutics for infectious diseases and other high public-health-burden indications. Core activities include human antibody discovery, siRNA/oligonucleotide therapeutics, vaccine and immunotherapy development, preclinical characterization, clinical development through late-stage trials, regulatory submissions, CMC/GMP manufacturing oversight, CDMO partnerships and regional commercialization with emphasis on Greater China and global public health impact. The company is publicly listed (HKEX: 2137.HK).
Industries
Nr. of Employees
medium (51-250)
Patents
Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof
US-12370200-B2
View DetailsCombination therapy for HIV with adenosine derivative and capsid inhibitors
US-12257264-B2
View DetailsCombination therapy for HIV with adenosine derivative and capsid inhibitors
US-11890297-B2
View Details
Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof
US-12370200-B2
View DetailsCombination therapy for HIV with adenosine derivative and capsid inhibitors
US-12257264-B2
View DetailsCombination therapy for HIV with adenosine derivative and capsid inhibitors
US-11890297-B2
View DetailsProducts
Neutralizing antibody therapeutic candidates for viral infections
Clinical- and preclinical-stage neutralizing antibody candidates derived from human B cells targeting viral pathogens for prevention or treatment.
siRNA and oligonucleotide therapeutic candidates
siRNA/oligonucleotide candidates targeting viral and hepatotropic disease pathways developed for gene-silencing therapy and evaluation in combination regimens.
Vaccine and immunotherapy candidates for chronic infectious disease
Recombinant-protein and other immunotherapy candidates developed to enhance pathogen-specific immune responses and used in combination strategies to improve cure rates.
Neutralizing antibody therapeutic candidates for viral infections
Clinical- and preclinical-stage neutralizing antibody candidates derived from human B cells targeting viral pathogens for prevention or treatment.
siRNA and oligonucleotide therapeutic candidates
siRNA/oligonucleotide candidates targeting viral and hepatotropic disease pathways developed for gene-silencing therapy and evaluation in combination regimens.
Vaccine and immunotherapy candidates for chronic infectious disease
Recombinant-protein and other immunotherapy candidates developed to enhance pathogen-specific immune responses and used in combination strategies to improve cure rates.
Services
Partnership-based programs for discovery and preclinical development of neutralizing antibodies and other therapeutics in collaboration with academic and industry partners.
Clinical trial design, operational execution and regulatory reporting across early and late stages for infectious disease therapeutics, including combination trials and biomarker-guided studies.
Consultative support for regulatory filings, chemistry‑manufacturing‑controls programs and GMP compliance, including CDMO oversight and technology transfer coordination.
Evaluation, negotiation and integration services for acquiring clinical-stage assets and intellectual property, plus management of associated supply continuity and technology transfer.
Partnership-based programs for discovery and preclinical development of neutralizing antibodies and other therapeutics in collaboration with academic and industry partners.
Clinical trial design, operational execution and regulatory reporting across early and late stages for infectious disease therapeutics, including combination trials and biomarker-guided studies.
Consultative support for regulatory filings, chemistry‑manufacturing‑controls programs and GMP compliance, including CDMO oversight and technology transfer coordination.
Evaluation, negotiation and integration services for acquiring clinical-stage assets and intellectual property, plus management of associated supply continuity and technology transfer.
Expertise Areas
- Monoclonal antibody discovery and development
- siRNA/oligonucleotide therapeutic development
- Clinical trial management and execution (Phase 1–3)
- Combination therapy development and biomarker‑guided studies
Key Technologies
- Single-cell sequencing for antibody identification
- Neutralization and microneutralization virology assays
- siRNA/oligonucleotide therapeutic platforms
- Pharmacokinetic study methodologies
News & Updates
Presentation of multiple abstracts and oral reports including interim data from an ongoing Phase 2 ENSURE study at the APASL meeting (Mar 26–30, 2025).
Management held a teleconference to discuss annual results and APASL presentations; session scheduled Mar 31, 2025 (Hong Kong time) / Mar 30, 2025 (US ET).
Annual results and company progress report, including asset acquisition updates, pipeline status and reported cash balance described as sufficient to fund operations into 2028.
Presentation of late-breaking ENSURE study data suggesting an immunotherapy candidate's role in advancing higher HBsAg loss.
Announcement of an exclusive collaboration to use an integrated antibody development and manufacturing technology platform for bispecific antibody discovery, development and production in China.
Memorandum to explore digital clinical research recruitment, patient education models and digital engagement tools to support clinical development.
Presentation of multiple abstracts and oral reports including interim data from an ongoing Phase 2 ENSURE study at the APASL meeting (Mar 26–30, 2025).
Management held a teleconference to discuss annual results and APASL presentations; session scheduled Mar 31, 2025 (Hong Kong time) / Mar 30, 2025 (US ET).
Annual results and company progress report, including asset acquisition updates, pipeline status and reported cash balance described as sufficient to fund operations into 2028.
Presentation of late-breaking ENSURE study data suggesting an immunotherapy candidate's role in advancing higher HBsAg loss.
Announcement of an exclusive collaboration to use an integrated antibody development and manufacturing technology platform for bispecific antibody discovery, development and production in China.
Memorandum to explore digital clinical research recruitment, patient education models and digital engagement tools to support clinical development.